I-Serosurveillance ibhekene nokulinganisa ukusabalala kwamasosha omzimba emphakathini ngokumelene ne-pathogen ethile.Isiza ukukala ukuvikeleka kwenani labantu ngemva kokutheleleka noma ukugonywa futhi inomsebenzi we-epidemiological ekulinganiseni ubungozi bokudlulisela kanye namazinga okuvikeleka kwesibalo sabantu.Kulolu bhubhane lwamanje lwe-coronavirus 2019 (COVID-19), i-serosurvey ibambe iqhaza elibalulekile ekuhloleni izinga langempela lokutheleleka nge-acute acute respiratory syndrome 2 (SARS-CoV-2) kubantu abahlukahlukene.Kusize futhi ukusungula izinkomba ze-epidemiologic, isb, i-infection fatality ratio (IFR).
Ekupheleni kuka-2020, kwase kushicilelwe ama-serosurveys angama-400.Lezi zifundo bezisekelwe ezinhlotsheni ezihlukene zama-immunoassays ezakhelwe ukuhlaziya amasosha omzimba ngokumelene ne-SARS-CoV-2, ikakhulukazi eqondise wonke noma ingxenye yamaphrotheni e-spike (S) kanye ne-nucleocapsid (N) ye-SARS-CoV-2.Esimeni samanje sobhubhane lwe-COVID-19, amagagasi obhubhane alandelana esenzeka ezifundeni ezihlukene zomhlaba, athelela ingxubevange yabantu abaningi ngesikhathi esithile.Lesi simo siphonse inselelo ukuhlolwa kwe-SARS-CoV-2 ngenxa yokwakheka kwezwe okuhlukahlukene kwe-immunological.
Ososayensi baye baqaphela ukuthi amazinga e-anti-SARS-CoV-2 antibody anomkhuba wokubola ngemva kwesikhathi sokululama.Isigameko esinjalo sandisa amathuba okuba nemiphumela engemihle ngama-immunoassays.Lawa ma-negethivu angamanga angabukela phansi ngokufanelekile izinga lokutheleleka kwangempela ngaphandle uma ebonwa futhi elungiswa ngokushesha.Ukwengeza, ama-antibody kinetics angemva kokutheleleka avela ngokuhlukile ngokuhambisana nobulukhuni bokutheleleka - ukutheleleka okunzima kakhulu kwe-COVID-19 kuvame ukufaka ukwanda okukhulu kwezinga lamasosha omzimba uma kuqhathaniswa nezifo ezithambile noma ezingenazimpawu.
Ucwaningo oluningana luveze ama-antibody kinetics izinyanga eziyisithupha ngemuva kokutheleleka.Lolu cwaningo luthole ukuthi iningi labantu emiphakathini etheleleke nge-SARS-CoV-2 bakhombisa izifo ezithambile noma ezingenazimpawu.Abacwaningi bakholelwa ukuthi kubalulekile ukulinganisa ushintsho kumazinga amasosha omzimba, kusetshenziswa ama-immunoassay atholakalayo, kulo lonke uhlobo olubanzi lobunzima bokutheleleka.Iminyaka yobudala nayo yayibhekwa njengento ebalulekile kulezi zifundo.
Ocwaningweni lwakamuva, ososayensi bathole amazinga e-anti-SARS-CoV-2 amasosha afika ezinyangeni eziyi-9 ngemuva kokutheleleka, futhi bashicilela abakutholilemedRxiv* Iseva yokuphrinta ngaphambili.Ocwaningweni lwamanje, iqoqo labantu abane-seropositive laqashwa ngokuhlolwa okwenziwe eGeneva, eSwitzerland.Abacwaningi basebenzise ama-immunoassay amathathu ahlukene, okungukuthi, i-semiquantitative anti-S1 ELISA yokuthola i-IgG (ebizwa ngokuthi i-EI), i-quantitative Elecsys anti-RBD (ebizwa ngokuthi, i-Roche-S) kanye ne-semiquantitative Elecsys anti-N (ebizwa ngokuthi i-Roche- N).Ucwaningo lwamanje lunikeza ukuqonda okubalulekile ezifundweni ze-serologic ezisekelwe kubantu futhi lubonisa ubunkimbinkimbi bendawo yokuzivikela komzimba ngenxa yengxubevange yokutheleleka kwe-COVID-19 yakamuva kanye ne-distal, kanye nokugoma.
Ucwaningo olucutshungulwayo lubike ukuthi abantu abathole i-COVID-19 abanezimpawu ezithambile noma ababengenayo i-asymptomatic, baveze ukuba khona kwamasosha omzimba.Lawa ma-antibodies aqondise ku-nucleocapsid (N) noma amaprotheni e-spike (S) e-SARS-CoV-2 futhi atholakala ephikelela okungenani izinyanga eziyi-8 ngemuva kokutheleleka.Kodwa-ke, ukutholwa kwabo kuncike kakhulu ekukhetheni kwe-immunoassay.Abaphenyi bathole ukuthi izilinganiso zokuqala zamasosha omzimba, athathwe kubahlanganyeli phakathi nezinyanga ezine nengxenye ze-COVID-19, bezihambisana kuzo zonke izinhlobo ezintathu zokuhlolwa kokuzivikela komzimba ezisetshenziswe kulolu cwaningo.Kodwa-ke, ngemva kwezinyanga ezine zokuqala, futhi kuze kufike ezinyangeni eziyisishiyagalombili ngemva kokutheleleka, imiphumela yahluka kuzo zonke izivivinyo.
Lolu cwaningo luveze ukuthi endabeni yokuhlolwa kwe-EI IgG, oyedwa kwabane ababambiqhaza wayene-sero-reverted.Kodwa-ke, kwamanye ama-immunoassays, afana ne-Roche anti-N kanye nokuhlolwa okuphelele kwe-Ig ye-Anti-RBD, kutholwe ukuguqulwa kwe-sero okumbalwa kuphela noma okungekho kusampula efanayo.Ngisho nabahlanganyeli abanezifo ezingelapheki, ngaphambili okwakucatshangwa ukuthi bathola izimpendulo zamasosha omzimba aqinile, babonise ukuzwela ngenkathi besebenzisa i-anti-RBD kanye ne-anti-N isamba sokuhlolwa kwe-Ig Roche.Kokubili ama-assays ahlala ebucayi isikhathi esingaphezu kwezinyanga eziyi-8 ngemuva kokutheleleka.Ngakho-ke, le miphumela iveze ukuthi womabili ama-Roche immunoassays afaneleka kakhulu ukulinganisa i-seroprevalence ngemuva kwesikhathi eside ngemuva kokutheleleka kokuqala.
Kamuva, besebenzisa ukuhlaziya kokulingisa, abacwaningi baphetha ngokuthi ngaphandle kwendlela yokulinganisa enembile, ikakhulukazi, uma kucatshangelwa ukuzwela kokuhlola okushintshashintshayo isikhathi, ukuhlola kwe-seroprevalence bekungeke kube okunembile.Lokhu kuzoholela ekubukelweni phansi kwenani langempela lezifo eziqongelelayo esizweni.Lolu cwaningo lwe-immunoassay lubonise ukuba khona komehluko kumazinga we-seropositivity phakathi kokuhlolwa okutholakalayo kwezohwebo.
Kumele kuqashelwe ukuthi kunemikhawulo eminingana yalolu cwaningo.Isibonelo, i-reagent esetshenziswe ngenkathi kuhlolwa i-EI kukho kokubili isisekelo (ukuhlolwa kokuqala noma koku-1) kanye nokulandelela (ukuhlolwa kwe-2 kwamakhandidethi afanayo) amasampula ngaphakathi kwesikhawu sesikhathi esithile ayehlukile.Omunye umkhawulo walolu cwaningo ukuthi ama-cohorts awazange afake izingane.Kuze kube manje, abukho ubufakazi bokuguquguquka kwe-antibody yesikhathi eside ezinganeni osekubhaliwe.
Isikhathi sokuthumela: Mar-24-2021